Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71806 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, online erschienen am 13.04.2026. Verfasst von Sang-A Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Kor…. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Consolidation Chemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seoul National University Bundang Hospital Research Fund.
Abstract (Originalsprache)
Background
The optimal consolidation strategy following high‐dose methotrexate (MTX)–based induction in primary central nervous system lymphoma (PCNSL) remains controversial. This study compared real‐world outcomes of different consolidation modalities in patients responsive to rituximab, MTX, vincristine, and procarbazine (R‐MVP) induction chemotherapy.
Methods
We retrospectively analyzed 296 newly diagnosed PCNSL patients treated with R‐MVP between 2008 and 2023. Among 290 evaluable patients, the overall response rate (ORR) was assessed, and survival outcomes were evaluated by Kaplan–Meier and Cox regression analyses. Propensity score matching (PSM) was performed to compare autologous stem‐cell transplantation (ASCT) and whole‐brain radiotherapy (WBRT).
Results
The ORR was 89.7%, with 71.7% achieving complete response (CR) or complete response unconfirmed (CRu) and 17.9% partial response (PR). Of 260 responders, 190 received consolidation: WBRT (40.8%), ASCT (20.0%), or non‐myelosuppressive chemotherapy (NMC; 12.3%). After a median follow‐up of 45.3 months, median progression‐free survival (PFS) and overall survival (OS) for responders were 65.8 (95% CI 50.7–80.8) and 84.6 months (95% CI 66.5–102.7), respectively. ASCT yielded the most favorable survival (median PFS not reached), followed by WBRT (70.8 months), whereas NMC and no‐consolidation groups showed significantly inferior PFS (22.9 and 40.1 months, p < 0.001). OS showed a similar trend ( p = 0.006). On multivariable analysis, elevated LDH and consolidation type were independent predictors of PFS, whereas age and consolidation type were significant prognostic factors for OS. In the PSM cohort (ASCT vs. WBRT, n = 52 each), median PFS was not reached for ASCT versus 90.0 months for WBRT ( p = 0.050); OS was not reached versus 97.9 months ( p = 0.160).
Conclusions
ASCT was associated with the most durable survival among consolidation strategies after R‐MVP induction. These findings, derived from a large real‐world, multi‐institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
- Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
- Department of Radiation Oncology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
- Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
ORCID-Profile: Sang-A Kim, Chul-Kee Park, Tae Min Kim
Förderung
- Seoul National University Bundang Hospital Research Fund
Zitieren
APA
Kim, S. A., Kim, J. S., Lee, J. Y., Lee, J. H., Eom, K. Y., Park, C. K., Kim, C. Y., Heo, D. S., Lee, J. O., & Kim, T. M. (2026). Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71806
Vancouver
Kim SA, Kim JS, Lee JY, Lee JH, Eom KY, Park CK, et al. Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71806
BibTeX
@article{Kim2026,
author = {Kim, Sang-A and Kim, Jung Sun and Lee, Ji Yun and Lee, Joo Ho and Eom, Keun-Yong and Park, Chul-Kee and Kim, Chae-Yong and Heo, Dae Seog and Lee, Jeong-Ok and Kim, Tae Min},
title = {Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71806}
}
EUVIMED